Olivia Esposito • December 22, 2023
The HCMA Theme for January is Setting Your Plan For The Year

You must advocate for yourself to ensure you get the best care for your HCM. An essential first step is having a plan that includes the tests you will likely need and how often you should see your cardiologist. To make this planning more manageable, the HCMA offers Navigation Calls. Members can take advantage of this every year. Non-members are encouraged to complete our  Intake and Navigation Call  at least once to help you get on track with your care. 

We encourage you to see an HCM expert at an  HCMA Recognized Center of Excellence (COE)  if possible, and we are continually expanding this program to give you more options. For those outside the US, we can often help you find an HCM expert, although we have yet to cover every country.

Is cost limiting your ability to take advantage of these services? The HCMA offers  scholarship memberships , and the  Lori Fund  can provide grants of up to $600 per year to cover the cost of traveling to a COE.

For HCM patients who are stable, here are some general guidelines for regular  testing

  • Annual Echocardiogram
  • Annual EKG and/or Ambulatory Monitor
  • Annual cardiologist visit
  • Cardiac MRI every 3-5 years

If your symptoms change, you should always contact your cardiology team to discuss whether a medication change or other treatment would help you stay stable. Make flexibility part of your plan to account for changes in your condition. Remember that each patient is different, and some can safely go 2-3 years between visits, while others may need to see their team every six months or less.

HCMA Blog

April 30, 2025
Medical Management means using medicines and other non-invasive therapies to relieve symptoms. It's exciting that new treatments for HCM are being studied and that the FDA approved Camzyos in 2022! HCM can cause various symptoms depending on how stiff the heart is, how much scarring (fibrosis) there is, and whether there is obstruction. Some people have no noticeable symptoms. Common symptoms are chest pain/pressure, shortness of breath, lightheadedness, fatigue, palpitations, and brain fog. Syncope (fainting) is dramatic but not as common as the other symptoms. Medications are the first-line treatment for symptoms of HCM. If patients can't take one class of medication, they can try a medication from a different class. Here are some medications used to treat HCM and what they're for: Beta Blockers - make your heart beat slower and relax better. They allow the heart to fill more completely between beats. They can lower blood pressure and relieve symptoms. Calcium Channel Blockers - used to lower blood pressure and slow the heart rate. May reduce symptoms from obstruction in HCM. Myosin Inhibitors - cause the heart to beat with less force. They may reduce obstruction and septal thickness in some patients. Camzyos (mavacamten) is the first of this class of medication. For more information, click HERE . Antiarrhythmics - help to restore normal rhythm in the heart. Blood Thinners - anticoagulants and anti-platelets make it harder for blood to clot. They are prescribed to reduce the risk of stroke. This risk is higher in patients with afib, aflutter, and artificial heart valves. Diuretics , or "water pills," help the kidneys get rid of extra water and salt, reducing swelling in the body. Sodium Channel Blockers - may reduce gradient in obstructive HCM and can treat chest pain. Some also act as antiarrhythmics. Antibiotics - treat or prevent bacterial infections. In HCM, they may be given before dental work to prevent infective endocarditis. To learn more and see the side effects of these medications, click HERE .
On a green background, a line drawing of a head that has complicated arrows pointing outwards
By Gordon Fox April 25, 2025
Part 2 of a series on making decisions in HCM. A key reason is that decision making is so difficult is that most decisions involve more than one risk.
Hypertrophic Obsctructive Cardiomyopathy
By Erica Friedman April 22, 2025
Bristol Myers Squibb announces that Camzyos has been approved for Obstructive Hypertrophic Cardiomyopathy in Japan.
More Posts